Eddy Shih-HsinYangMDPhD

Breast Cancer, Head & Neck, Urologic Cancer

Professor and Vice Chair for Translational Sciences, Department of Radiation Oncology Deputy Director and Associate Director of Precision Oncology Hugh Kaul Precision Medicine Institute, University of Alabama School of Medicine

Join to view full profile

Dr. Yang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Yang's full profile

Already have an account?

Office
800 Rose St
Lexington, KY 40536
Phone+1 859-257-7618

Fax+1 859-257-4060

Education & Training

Vanderbilt University Medical CenterResidency, Radiation Oncology, 2006 - 2010
Mount Sinai Medical Center of FloridaInternship, Internal Medicine, 2005 - 2006
University of Miami Leonard M. Miller School of MedicineClass of 2005

Certifications & Licensure

AL State Medical License 2010 - 2025
KY State Medical License 2023 - 2025
American Board of Radiology Radiation Oncology

Clinical Trials

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Start of enrollment: 2016 Mar 14
Recruiting
Phase 2
International Registry for Men With Advanced Prostate Cancer (IRONMAN) Start of enrollment: 2017 Jul 21
Recruiting
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Start of enrollment: 2019 Sep 06
Recruiting
Phase 1, Phase 2
⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors Start of enrollment: 2018 Dec 18
Completed
Phase 2
Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer Start of enrollment: 2019 Oct 08
Terminated
Phase 2
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer Start of enrollment: 2020 Feb 11
Active, not recruiting
Phase 3
Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer Start of enrollment: 2021 Feb 25
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer WithAlterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Timothy L Cannon, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Vi K Chiu
Journal of Clinical Oncology. 2024-09-20
Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor.
Zeta Chow, Jeremy Johnson, Aman Chauhan, Jong Cheol Jeong, Jennifer T Castle
Cancer Letters. 2024-08-01
4 citations
BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine.
Aubrey L Miller, Samuel C Fehling, Rebecca B Vance, Dongquan Chen, Eric Josh Brown
Cancer Letters. 2024-06-28

Lectures

Incorporating Transcriptomics to Guide Precision Therapeutics. Innovative Immune and Genomic Biomarkers for Solid Tumors
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018